Trial Profile
Cost-Consequence Analysis of Switching from an Oral Antipsychotic to Long Acting Injectable Risperidone Among Patients with Schizophrenia
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Dec 2011
Price :
$35
*
At a glance
- Drugs Risperidone (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- Acronyms SMART
- 06 Dec 2011 New trial record
- 08 Nov 2011 Results presented at the 14th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.